# Acute Pancreatitis Market

> Acute Pancreatitis Market Research Report: Size, Share, Trend Analysis By Cause (Gallstones, Alcohol and Others), By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others), By Diagnosis (Imaging Tests and Laboratory Tests), By End-User (Hospitals, Clinics and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.84%
- **2024:** $ 6.58 Billion
- **2025:** $ 7.36 Billion
- **2035:** $ 22.52 Billion
- **Key Players:** AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Fresenius Kabi (DE), Mylan (US), Novartis (CH), Sanofi (FR), Teva Pharmaceutical Industries (IL), Merck & Co. (US) – key contributors shaping the competitive landscape of the acute pancreatitis market.

**Report ID:** MRFR/Pharma/1036-CR · **Pages:** 118 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 04, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565

---

## Market Summary

## **Acute Pancreatitis Market Overview**

Acute Pancreatitis Market Size was valued at USD 5.88 Billion in 2023. The Global Acute Pancreatitis industry is projected to grow from USD 6.29 Billion in 2024 to USD 18.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.70% during the forecast period (2024 - 2032). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Orphan Drug Designation Has Been Granted to Olezarsen, an Investigational Medicine Developed by Ionis Pharmaceuticals, Inc. for the Treatment of Familial Chylomicronemia Syndrome (FCS), a Rare Genetic Disease That Causes Very High Triglyceride Levels in the Body Followed by Recurrent Acute Pancreatitis (AP), by FDA. When a drug is used to diagnose, prevent or treat diseases that affect less than 200000 people at the time of use, it is considered an orphan drug. 

Among these enzymes, FCS specifically affects the fats’ disintegration process, and fasting triglyceride levels can increase up to 10-100 times more than is common. The inflammation may cause hospitalization due to severe pancreatitis AP that can be fatal. People with FCS are prone to developing conditions like AP that inflame the pancreas, thus causing hospitalization, which might be lethal. Harsher instances hurt critical organs like the lungs, heart, kidney, liver, and pancreas.

UCB announced today that ZILBRYSQ® (zilucoplan) has been approved by the FDA as a new treatment for adult patients suffering from generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. An option of daily subcutaneous regimen2 provides zilucoplan, which is an important C5 inhibitot2 with peptide targeting. 

Besides others, it is anticholinesterase among adults with AChR antibody-positive gMG.Its specific mechanisms inhibiting complement-mediated damage at NMJ act as C5 complement inhibitor2, allowing zilucoplan. While advantages of self-administration do exist when patients receive therapy from home without necessarily going back to the hospital, among other things, this saves time when commutated between different locations and consequently allows patients to have more control over their lives.

Zydus Lifesciences Limited (hereinafter referred to as ‘Zydus’, including its subsidiaries/affiliates) announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg. Glycemic levels in type-2 diabetes mellitus patients can be managed with ZITUVIO alongside dieting and exercising. 

The approval of ZITUVIO™ is based on research, development, regulatory, and manufacturing work performed by Zydus teams. Nitrosamine testing results and potential genotoxic impurities were within acceptable limits as per current USFDA standards. Nitrosamines content in ZITUVIO™ Sitagliptin-containing products meets the standards set by the current USFDA guidelines regarding Nitrosamines.

## **Acute Pancreatitis Market Trends**

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 275,000 Americans are hospitalized for acute pancreatitis yearly (NIDDK). When the pancreas swells up and becomes irritated, pancreatitis results (swollen). It is not a widespread illness. The most common reasons are gallstones or binge drinking. 

The illness may grow gradually over time or manifest suddenly, causing great injury. Treatment for pancreatitis may include intravenous (IV) fluids, painkillers, and other medicines. The increase in the occurrence of acute pancreatitis on a global scale will be a key factor in the market's increased growth rate. Gallstones and heavy drinking, especially among younger people, are the main causes of acute pancreatitis. 

Gallstones are the most frequent cause of AP, accounting for 28 to 38 percent of cases, and alcohol consumption is the second-most common cause, accounting for 19 to 41 percent of cases, according to an article published in the World Journal of Clinical Cases- Evaluation and management of acute pancreatitis in 2019. The likelihood of developing acute pancreatitis increases as the number of people with gallstones rises. Thus, this factor is driving the market CAGR.

Furthermore, globally, chronic comorbidities are becoming more common, and there is an increasing curiosity about how these comorbidities affect those with acute pancreatitis. In the early stages of acute pancreatitis, for instance, it has been discovered that gastrointestinal symptoms are linked to pre-existing metabolic syndrome, obesity, diabetes mellitus, and metabolic syndrome, according to a research paper published in BioMed Hub in November 2021. 

A PLOS One paper from June 2021 claims that obesity is also a big public health issue in France because it increases the likelihood of developing chronic conditions, including diabetes, hypertension, and other conditions with severe psychological and social repercussions. As a result, the increasing prevalence of obesity raises people's chance of getting pancreatitis due to overeating habits, which is expected to drive the segment's rise over the forecast period. 

The studied market is therefore anticipated to expand throughout the forecast period due to variables like the rising prevalence of obesity and the growing utilization of IV therapy.

However, the market will grow due to an increase in the elderly population and government measures to raise awareness. Along with this, shifting consumer lifestyles and expanding government-welcoming measures will accelerate market expansion. A rise in the quantity of R&D activities is another factor driving the market's expansion. Thus, it is anticipated that this aspect will accelerate acute pancreatitis market revenue globally.

## **Acute Pancreatitis Market Segment Insights:**

### **Acute Pancreatitis Cause Insights**

The Acute Pancreatitis Market segmentation, based on cause, includes gallstones, alcohol and others. The gallstones segment held the majority share in 2022 in the Acute Pancreatitis Market data. Globally, the prevalence of acute pancreatitis is rising along with the frequency of gallstones. About 40% of cases of acute pancreatitis are brought on by gallstones. Gallstones affect about 20 million people in the US. Each year, about 300,000 cholecystectomies are performed on these patients.

### **Acute Pancreatitis Treatment Insights**

The Acute Pancreatitis Market segmentation, based on treatment, includes intravenous fluid, nutritional support, analgesics, endoscopic retrograde cholangiopancreatography (ERCP) and others. The intravenous fluid segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032 due to variables including the increased prevalence of acute pancreatitis, gallstones, and obesity in the population, as well as the risk factors that go along with them. 

Dehydration and severe fluid loss are associated with acute pancreatitis, which can be fatal and may result in the patient dying. The body is kept hydrated through intravenous fluid delivery, ensuring appropriate blood flow to all other organs.

### **Acute Pancreatitis Diagnosis Insights**

The Acute Pancreatitis Market data, based on diagnosis, includes imaging tests and laboratory tests. The laboratory tests segment dominated the acute pancreatitis market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Amylase and lipase are crucial pancreatic enzymes diagnosed with laboratory tests. The following could cause one's blood to spill. Other blood tests can also be used to check for gallbladder blockage or damage.

**Figure 2: Acute Pancreatitis Market, by Diagnosis, 2023 & 2032 (USD Billion)** 

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review **Acute Pancreatitis End-User Insights**

The global acute pancreatitis industry, based on end-user, includes hospitals, clinics and others. The hospitals segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The fact that hospitals are always well-stocked with all services available under one roof encourages patients with acute pancreatitis to go there for care. Another reason driving up hospital visits is the growing penetration of linked gadgets and equipment.

**Acute Pancreatitis Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America acute pancreatitis market accounted for USD 2.5 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The prevalence of acute pancreatitis, obesity, and gallstone instances is rising. These conditions and the presence of a well-established healthcare infrastructure and high healthcare spending are all driving the market's expansion.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: ACUTE PANCREATITIS MARKET SHARE BY REGION 2022 (%)** 

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Asia Pacific acute pancreatitis market accounts for the second-largest market share. The risk of having pancreatic inflammation has increased due to the population's rising incidence of obesity due to their changing lifestyles, which is anticipated to drive market expansion. 

Acute pancreatitis medication and device-based therapies are expected to be in high demand, driving market expansion thanks to the region's expanding research and development efforts. Moreover, China acute pancreatitis market held the largest market share, and the India acute pancreatitis market was the fastest growing market in the region.

Europe acute pancreatitis Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because the demand for particular treatments is increasing, and rising healthcare costs will further accelerate the market's growth rate in this area. The presence of important players and increased use of newer technologies will also accelerate the market's growth rate in this area. Further, the UK acute pancreatitis market held the largest market share, and the Germany acute pancreatitis market was the fastest growing market in the region.

**Acute Pancreatitis Key Market Players & Competitive Insights**

Major market players are spending a lot of money on R&D to increase their product lines, which will help the acute pancreatitis market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the acute pancreatitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global acute pancreatitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, acute pancreatitis industry has provided medicine with some of the most significant benefits.

The acute pancreatitis market major player such as SCM Lifescience, General Electric Company, CalciMedica, B. Braun Melsungen AG, Samsung Bioepis, Medtronic, Boston Scientific Corporation, Baxter International Inc., Fresenius Kabi USA, and GNT Pharma Co.

CalciMedica, a biopharmaceutical company in the clinical stage for the treatment of inflammatory illnesses like COVID-19 pneumonia and acute pancreatitis, are developing inhibitors of CRAC channels. Calcium, a crucial messenger chemical, must be transported into different types of cells through CRAC channels. 

CalciMedica has created a portfolio of wholly-owned CRAC channel inhibitors and unique assays to maximize chemical leads. In December 2022, auxora is the subject of Phase II clinical dose-ranging study by CalciMedica, Inc. in patients with acute pancreatitis and systemic inflammatory response syndrome.

The corporate headquarters of the American healthcare giant Baxter International Inc. is located in Deerfield, Illinois. The company's main areas of concentration include chronic and urgent medical issues, including kidney illness. Sales for the company's two segments, BioScience and Medical Products, totaled $10.6 billion in 2017. Recombinant and blood plasma proteins, plasma-based therapies, products for regenerative medicine, and vaccines are all produced by Baxter's BioScience division to treat hemophilia and other bleeding disorders, immunological deficiencies, and other chronic and acute blood-related illnesses.

**Key Companies in the acute pancreatitis market includes**

### Acute Pancreatitis Market Industry Developments

- **Q2 2024: Takeda Announces FDA Approval of Takhzyro (lanadelumab) for Prevention of Acute Pancreatitis Attacks in Patients with Hereditary Angioedema** Takeda received FDA approval for Takhzyro (lanadelumab) as a preventive treatment for acute pancreatitis attacks in patients with hereditary angioedema, marking a significant regulatory milestone for the company in the acute pancreatitis market.
- **Q1 2024: Novartis Launches Phase III Clinical Trial for New Acute Pancreatitis Therapy** Novartis announced the initiation of a Phase III clinical trial evaluating a novel therapeutic candidate for the treatment of acute pancreatitis, aiming to address unmet medical needs in this indication.
- **Q2 2024: Pfizer and BioNTech Enter Strategic Partnership to Develop mRNA-based Therapy for Acute Pancreatitis** Pfizer and BioNTech announced a strategic partnership to co-develop an mRNA-based therapeutic targeting acute pancreatitis, leveraging their expertise in mRNA technology for new indications.
- **Q3 2024: GSK Acquires PancreaTech to Expand Acute Pancreatitis Pipeline** GlaxoSmithKline completed the acquisition of PancreaTech, a biotech company focused on novel treatments for acute pancreatitis, to strengthen its pipeline in gastrointestinal diseases.
- **Q2 2025: AbbVie Receives EMA Approval for New Acute Pancreatitis Drug, Pancrelix** AbbVie announced that the European Medicines Agency (EMA) approved Pancrelix, a new drug for the treatment of acute pancreatitis, expanding its portfolio in the gastrointestinal therapeutic area.
- **Q1 2025: Startup PancreoMed Raises $40 Million Series B to Advance Acute Pancreatitis Therapy** PancreoMed, a biotech startup developing a novel therapy for acute pancreatitis, secured $40 million in Series B funding to support clinical development and regulatory submissions.
- **Q2 2024: Sanofi and Mayo Clinic Announce Research Collaboration on Acute Pancreatitis Biomarkers** Sanofi and Mayo Clinic entered a research collaboration to identify and validate new biomarkers for early diagnosis and prognosis of acute pancreatitis.
- **Q3 2024: Vertex Pharmaceuticals Opens New Manufacturing Facility for Acute Pancreatitis Drug Production** Vertex Pharmaceuticals inaugurated a new manufacturing facility dedicated to the production of its investigational acute pancreatitis drug, aiming to scale up supply for late-stage clinical trials.
- **Q1 2025: BioPancreas Inc. Files for IPO to Fund Acute Pancreatitis Drug Development** BioPancreas Inc. filed for an initial public offering (IPO) to raise capital for the development and commercialization of its lead acute pancreatitis drug candidate.
- **Q2 2025: Takeda Appoints Dr. Maria Lopez as Head of Acute Pancreatitis Program** Takeda announced the appointment of Dr. Maria Lopez as the new Head of its Acute Pancreatitis Program, reflecting the company's commitment to advancing its pipeline in this therapeutic area.
- **Q3 2024: AstraZeneca Signs Licensing Agreement with PancreaGen for Acute Pancreatitis Drug Candidate** AstraZeneca entered into a licensing agreement with PancreaGen to develop and commercialize a promising acute pancreatitis drug candidate, expanding its presence in the gastrointestinal market.
- **Q1 2024: Johnson & Johnson Invests in AI Startup Focused on Acute Pancreatitis Diagnostics** Johnson & Johnson made a strategic investment in an AI startup developing advanced diagnostic tools for acute pancreatitis, aiming to improve early detection and patient outcomes.

## **Acute Pancreatitis Market Segmentation**

### **Acute Pancreatitis Cause Outlook (USD Billion, 2024-2032)**

### **Acute Pancreatitis Treatment Outlook (USD Billion,****2023-2032****)**

### **Acute Pancreatitis Diagnosis Outlook (USD Billion, 2023-2032)**

### **Acute Pancreatitis End-user Outlook (USD Billion, 2023-2032)**

### **Acute Pancreatitis Regional Outlook (USD Billion, 2023-2032)**

## Market Drivers

### Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the Acute Pancreatitis Market. The development of novel therapeutic agents, including enzyme replacements and minimally invasive surgical techniques, has transformed patient management. For instance, the introduction of endoscopic interventions has shown promising results in managing complications associated with acute pancreatitis. Furthermore, the market is witnessing a shift towards personalized treatment approaches, which are tailored to individual patient profiles. This evolution in treatment strategies not only enhances patient outcomes but also drives market growth as healthcare providers seek to adopt the latest advancements in the Acute Pancreatitis Market.

### Rising Incidence of Acute Pancreatitis

The increasing incidence of acute pancreatitis is a primary driver for the Acute Pancreatitis Market. Recent data indicates that the prevalence of this condition has been on the rise, with estimates suggesting that approximately 34 cases per 100,000 individuals occur annually. This trend is attributed to factors such as dietary changes, increased alcohol consumption, and the growing prevalence of obesity. As the number of cases escalates, the demand for effective treatment options and diagnostic tools within the Acute Pancreatitis Market is likely to surge, prompting pharmaceutical companies and healthcare providers to invest in innovative solutions to address this pressing health issue.

### Growing Awareness and Education Initiatives

The rise in awareness and education initiatives surrounding acute pancreatitis is a crucial driver for the Acute Pancreatitis Market. Healthcare organizations and advocacy groups are actively promoting knowledge about the condition, its risk factors, and the importance of early diagnosis and treatment. This heightened awareness is likely to lead to increased patient engagement and a greater willingness to seek medical attention, ultimately resulting in higher diagnosis rates. As more individuals become informed about acute pancreatitis, the demand for diagnostic tools and treatment options within the Acute Pancreatitis Market is expected to grow, fostering a more proactive approach to managing this condition.

### Regulatory Support for Innovative Therapies

Regulatory support for innovative therapies is playing a significant role in shaping the Acute Pancreatitis Market. Regulatory agencies are increasingly recognizing the need for expedited approval processes for new treatments that address unmet medical needs in acute pancreatitis. This supportive environment encourages pharmaceutical companies to invest in the development of groundbreaking therapies. For example, recent initiatives aimed at streamlining the approval of novel drugs have the potential to bring effective treatments to market more rapidly. As a result, the Acute Pancreatitis Market is likely to benefit from a more diverse range of therapeutic options, ultimately improving patient care and outcomes.

### Increased Research and Development Investments

The Acute Pancreatitis Market is experiencing a surge in research and development investments, which is pivotal for its growth. Pharmaceutical companies and research institutions are allocating substantial resources to explore new therapeutic targets and improve existing treatment protocols. Recent reports indicate that R&D spending in the gastrointestinal sector, which includes acute pancreatitis, has increased by over 15% in the past few years. This influx of funding is expected to accelerate the discovery of novel drugs and treatment options, thereby enhancing the overall landscape of the Acute Pancreatitis Market and providing patients with more effective solutions.

## Future Outlook

The Acute Pancreatitis Market is projected to grow at 11.84% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing prevalence, and enhanced diagnostic technologies.

**New opportunities:**

- Development of personalized treatment protocols for acute pancreatitis patients. Expansion of telehealth services for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) and consultations. Investment in AI-driven diagnostic tools to improve early detection and management.

By 2035, the Acute Pancreatitis Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Cause: Gallstones (Largest) vs. Alcohol (Fastest-Growing)

In the Acute Pancreatitis Market, the cause segment is primarily dominated by [gallstones](https://www.marketresearchfuture.com/reports/gallstone-market-1935), which account for a significant share of cases. Gallstones are a leading risk factor for acute pancreatitis, contributing to around 30-40% of the cases. On the other hand, Alcohol-related pancreatitis is rapidly emerging, particularly among younger demographics, contributing new dimensions to acute pancreatitis market insights and shaping prevention strategies. This shift indicates a changing landscape in the causes behind acute pancreatitis, emphasizing the need for targeted public health strategies to address these factors.

Gallstones (Dominant) vs. Alcohol (Emerging)

Gallstones have long been recognized as the dominant cause of acute pancreatitis, significant due to their high incidence and strong correlation with dietary and lifestyle factors. Patients with gallstones often present with severe abdominal pain and require prompt medical attention. In contrast, alcohol is emerging as a noteworthy contributor, particularly among younger populations, where increased consumption and binge drinking behaviors are becoming prevalent. The impact of alcohol on pancreatic health is substantial, not only leading to acute cases but also posing chronic risks. This dual landscape of causes necessitates comprehensive prevention and treatment strategies tailored to address both dominant and emerging factors.

### By Treatment: Intravenous Fluid (Largest) vs. Nutritional Support (Fastest-Growing)

The Acute Pancreatitis Market is characterized by a diverse range of treatment options, with intravenous fluids representing the largest segment due to their critical role in patient management. Following this, Nutritional support is emerging rapidly, contributing positively to overall acute pancreatitis market size growth. Other treatments like analgesics and endoscopic retrograde cholangiopancreatography (ERCP) are also essential but represent smaller portions of the market.

Intravenous Fluid (Dominant) vs. Nutritional Support (Emerging)

Intravenous fluid therapy stands as the dominant treatment option for acute pancreatitis, primarily due to its role in preventing dehydration and maintaining electrolyte balance in patients. This therapeutic approach is essential in the early stages of treatment. Meanwhile, nutritional support is emerging as a critical component as well, with a growing emphasis on enteral feeding and nutritional assessments to enhance patient recovery. This shift in focus highlights a broader understanding of the disease management, where addressing nutritional needs is recognized as paramount for improving outcomes and reducing complications, thereby driving the growth of this segment.

### By Diagnosis: Imaging Tests (Largest) vs. Laboratory Tests (Fastest-Growing)

In the Acute Pancreatitis Market, the diagnosis segment is primarily dominated by Imaging Tests, which account for the largest share of market demand. Imaging techniques such as CT scans and MRI play a crucial role in visualizing pancreatic inflammation and complications, making them essential in diagnosis. Conversely, Laboratory Tests, which are emerging rapidly in this sector, are gaining traction due to their efficiency in identifying biomarkers and enzyme levels indicative of pancreatitis, thus enhancing diagnostic accuracy.

Diagnostic Methods: Imaging Tests (Dominant) vs. Laboratory Tests (Emerging)

Imaging Tests dominate the Acute Pancreatitis Market diagnostic landscape due to their ability to provide detailed visual assessments of pancreatic conditions. Techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are pivotal for identifying pancreatic abnormalities and complications associated with acute pancreatitis. While Imaging Tests remain the go-to solution for visualization, Laboratory Tests are rapidly emerging as significant players within the diagnosis segment. These tests are focused on analyzing enzyme levels and biomarkers, offering a quicker and less invasive approach to diagnosing acute pancreatitis. The growing emphasis on early diagnosis has contributed to the increasing reliance on Laboratory Tests, positioning them as a vital component of the diagnostic protocol.

### By End-user: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Acute Pancreatitis Market, the distribution of end-user segments is significantly skewed, with hospitals capturing the largest share. They serve as critical hubs for patient care, particularly for severe cases requiring comprehensive treatment. Clinics, while smaller in market share compared to hospitals, are emerging as a vital segment, primarily serving patients needing outpatient care and follow-ups. This dual structure is indicative of the varying complexities of pancreatitis treatment across the healthcare system. The growth trajectory for these segments reflects the increasing prevalence of acute pancreatitis, driving demand for hospital services. Furthermore, the trend towards outpatient care is boosting clinic visits as patients seek less intensive treatment options. Innovations in treatment methodologies and patient management in both settings are likely to further influence market dynamics as healthcare providers adapt to meet evolving patient needs.

Hospitals (Dominant) vs. Clinics (Emerging)

The hospital segment remains the dominant force within the Acute Pancreatitis Market, given their capability to handle critical care more effectively. Hospitals typically possess advanced facilities, including intensive care units, which are essential for managing severe cases of pancreatitis. They offer a comprehensive range of diagnostic and therapeutic services, making them a preferred choice for patients requiring specialized interventions. On the other hand, clinics are increasingly recognized as an emerging segment, catering to patients seeking less invasive treatments and follow-up care. The convenience of outpatient services provided by clinics resonates well with patients, leading to their growing popularity. Both segments play a crucial role in the overall healthcare landscape, catering to diverse patient needs.

## Regional Market Share Analysis

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America acute pancreatitis market accounted for USD 2.5 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The prevalence of acute pancreatitis, obesity, and gallstone instances is rising. These conditions and the presence of a well-established healthcare infrastructure and high healthcare spending are all driving the market's expansion.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Asia Pacific acute pancreatitis market accounts for the second-largest market share. The risk of having pancreatic inflammation has increased due to the population's rising incidence of obesity due to their changing lifestyles, which is anticipated to drive market expansion. 

Acute pancreatitis medication and device-based therapies are expected to be in high demand, driving market expansion thanks to the region's expanding research and development efforts. Moreover, China acute pancreatitis market held the largest market share, and the [India acute pancreatitis](https://www.marketresearchfuture.com/reports/india-acute-pancreatitis-market-56490) market was the fastest growing market in the region.

Europe acute pancreatitis Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because the demand for particular treatments is increasing, and rising healthcare costs will further accelerate the market's growth rate in this area. The presence of important players and increased use of newer technologies will also accelerate the market's growth rate in this area. Further, the UK acute pancreatitis market held the largest market share, and the Germany acute pancreatitis market was the fastest growing market in the region.

## Competitive Benchmarking

Major market players are spending a lot of money on R&D to increase their product lines, which will help the acute pancreatitis market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the acute pancreatitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global acute pancreatitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, acute pancreatitis industry has provided medicine with some of the most significant benefits.
The acute pancreatitis market major player such as SCM Lifescience, General Electric Company, CalciMedica, B. Braun Melsungen AG, Samsung Bioepis, Medtronic, Boston Scientific Corporation, Baxter International Inc., Fresenius Kabi USA, and GNT Pharma Co.
CalciMedica, a biopharmaceutical company in the clinical stage for the treatment of inflammatory illnesses like COVID-19 pneumonia and acute pancreatitis, are developing inhibitors of CRAC channels. Calcium, a crucial messenger chemical, must be transported into different types of cells through CRAC channels. 
CalciMedica has created a portfolio of wholly-owned CRAC channel inhibitors and unique assays to maximize chemical leads.
In December auxora is the subject of Phase II clinical dose-ranging study by CalciMedica, Inc. in patients with acute pancreatitis and systemic inflammatory response syndrome.
The corporate headquarters of the American healthcare giant Baxter International Inc. is located in Deerfield, Illinois. The company's main areas of concentration include chronic and urgent medical issues, including kidney illness. Sales for the company's two segments, BioScience and Medical Products, totaled $10.6 billion in 2017. Recombinant and blood plasma proteins, plasma-based therapies, products for regenerative medicine, and vaccines are all produced by Baxter's BioScience division to treat hemophilia and other bleeding disorders, immunological deficiencies, and other chronic and acute blood-related illnesses.

## Recent News & Developments

- **Q2 2024: Takeda Announces FDA Approval of Takhzyro (lanadelumab) for Prevention of Acute Pancreatitis Market Attacks in Patients with Hereditary Angioedema** Takeda received FDA approval for Takhzyro (lanadelumab) as a preventive treatment for acute pancreatitis attacks in patients with hereditary angioedema, marking a significant regulatory milestone for the company in the acute pancreatitis market.
- **Q1 2024: Novartis Launches Phase III Clinical Trial for New Acute Pancreatitis Market Therapy** Novartis announced the initiation of a Phase III clinical trial evaluating a novel therapeutic candidate for the treatment of acute pancreatitis, aiming to address unmet medical needs in this indication.
- **Q2 2024: Pfizer and BioNTech Enter Strategic Partnership to Develop mRNA-based Therapy for Acute Pancreatitis Market** Pfizer and BioNTech announced a strategic partnership to co-develop an mRNA-based therapeutic targeting acute pancreatitis, leveraging their expertise in mRNA technology for new indications.
- **Q3 2024: GSK Acquires PancreaTech to Expand Acute Pancreatitis Market Pipeline** GlaxoSmithKline completed the acquisition of PancreaTech, a biotech company focused on novel treatments for acute pancreatitis, to strengthen its pipeline in gastrointestinal diseases.
- **Q2 2025: AbbVie Receives EMA Approval for New Acute Pancreatitis Market Drug, Pancrelix** AbbVie announced that the European Medicines Agency (EMA) approved Pancrelix, a new drug for the treatment of acute pancreatitis, expanding its portfolio in the [gastrointestinal therapeutic](https://www.marketresearchfuture.com/reports/gastrointestinal-therapeutic-market-42431) area.
- **Q1 2025: Startup PancreoMed Raises $40 Million Series B to Advance Acute Pancreatitis Market Therapy** PancreoMed, a biotech startup developing a novel therapy for acute pancreatitis, secured $40 million in Series B funding to support clinical development and regulatory submissions.
- **Q2 2024: Sanofi and Mayo Clinic Announce Research Collaboration on Acute Pancreatitis Market Biomarkers** Sanofi and Mayo Clinic entered a research collaboration to identify and validate new biomarkers for early diagnosis and prognosis of acute pancreatitis.
- **Q3 2024: Vertex Pharmaceuticals Opens New Manufacturing Facility for Acute Pancreatitis Market Drug Production** Vertex Pharmaceuticals inaugurated a new manufacturing facility dedicated to the production of its investigational acute pancreatitis drug, aiming to scale up supply for late-stage clinical trials.
- **Q1 2025: BioPancreas Inc. Files for IPO to Fund Acute Pancreatitis Market Drug Development** BioPancreas Inc. filed for an initial public offering (IPO) to raise capital for the development and commercialization of its lead acute pancreatitis drug candidate.
- **Q2 2025: Takeda Appoints Dr. Maria Lopez as Head of Acute Pancreatitis Market Program** Takeda announced the appointment of Dr. Maria Lopez as the new Head of its Acute Pancreatitis Market Program, reflecting the company's commitment to advancing its pipeline in this therapeutic area.
- **Q3 2024: AstraZeneca Signs Licensing Agreement with PancreaGen for Acute Pancreatitis Market Drug Candidate** AstraZeneca entered into a licensing agreement with PancreaGen to develop and commercialize a promising acute pancreatitis drug candidate, expanding its presence in the gastrointestinal market.
- **Q1 2024: Johnson & Johnson Invests in AI Startup Focused on Acute Pancreatitis Market Diagnostics** Johnson & Johnson made a strategic investment in an AI startup developing advanced diagnostic tools for acute pancreatitis, aiming to improve early detection and patient outcomes.

## Report Scope

| MARKET SIZE 2024 | 6.576(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.355(USD Billion) |
| MARKET SIZE 2035 | 22.52(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.84% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Fresenius Kabi (DE), Mylan (US), Novartis (CH), Sanofi (FR), Teva Pharmaceutical Industries (IL), Merck & Co. (US) |
| Segments Covered | Cause, Treatment, Diagnosis, End-User, Region |
| Key Market Opportunities | Advancements in minimally invasive surgical techniques enhance treatment options in the Acute Pancreatitis Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the Acute Pancreatitis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Acute Pancreatitis Market as of 2024?**
A: The Acute Pancreatitis Market was valued at 6.576 USD Billion in 2024.

**Q: What is the projected market size for the Acute Pancreatitis Market in 2035?**
A: The market is projected to reach 22.52 USD Billion by 2035.

**Q: What is the expected CAGR for the Acute Pancreatitis Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Acute Pancreatitis Market during 2025 - 2035 is 11.84%.

**Q: Which companies are considered key players in the Acute Pancreatitis Market?**
A: Key players include AbbVie, Amgen, Bristol-Myers Squibb, Fresenius Kabi, Mylan, Novartis, Sanofi, Teva Pharmaceutical Industries, and Merck & Co.

**Q: What are the primary causes of Acute Pancreatitis and their market valuations?**
A: Gallstones and alcohol are primary causes, with market valuations of 2.5 to 8.5 USD Billion and 2.0 to 7.0 USD Billion, respectively.

**Q: What treatment segments are included in the Acute Pancreatitis Market?**
A: Treatment segments include intravenous fluid, nutritional support, analgesics, and ERCP, with valuations ranging from 1.0 to 5.0 USD Billion.

**Q: How does the diagnosis segment of the Acute Pancreatitis Market perform?**
A: The diagnosis segment includes imaging tests and laboratory tests, with valuations of 2.5 to 8.5 USD Billion and 4.076 to 14.04 USD Billion, respectively.

**Q: What are the end-user segments in the Acute Pancreatitis Market?**
A: End-user segments consist of hospitals, clinics, and others, with valuations of 3.5 to 12.1 USD Billion and 2.5 to 8.5 USD Billion.

**Q: What factors contribute to the growth of the Acute Pancreatitis Market?**
A: Factors contributing to growth include increasing incidence rates and advancements in treatment options, driving market expansion.

**Q: How does the Acute Pancreatitis Market compare to other gastrointestinal markets?**
A: The Acute Pancreatitis Market appears to be growing at a robust pace, potentially outpacing other gastrointestinal markets due to its specific treatment needs.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565*